Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 10/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.39 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15563693 | 0.87 | SIRT3 (0.59) | SIRT3TDP1KDM5AGPBAR1TACR1 | |
| SCHEMBL21227703 | 0.82 | SIRT3 (0.54) | SIRT3TDP1GPBAR1TACR1HSD17B1 | |
| SCHEMBL17157497 | 0.82 | SIRT3 (0.54) | SIRT3TDP1GPBAR1TACR1HSD17B1 | |
| SCHEMBL24941110 | 0.82 | SIRT3 (0.54) | SIRT3TDP1KDM5AGPBAR1TACR1 | |
| SCHEMBL18757900 | 0.81 | TDP1 (0.43) | SIRT3TDP1KDM5ATACR1PKN1 | |
| SCHEMBL12261135 | 0.81 | KDM5A (0.44) | SIRT3TDP1KDM5APKN1PKN2 | |
| SCHEMBL16931058 | 0.80 | SIRT3 (0.51) | SIRT3TDP1KDM5AGPBAR1TACR1 | |
| SCHEMBL21227634 | 0.80 | SIRT3 (0.51) | SIRT3TDP1GPBAR1TACR1HSD17B1 | |
| SCHEMBL5700424 | 0.79 | TDP1 (0.42) | SIRT3TDP1KDM5APKN1PKN2 | |
| SCHEMBL827419 | 0.79 | ROCK2 (0.51) | SIRT3TDP1KDM5AGPBAR1PKN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-11560381-B1 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-3362100-B1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH INC (US) | 2022-06-22 | — | — | EP | disclosed |
| US-10729738-B2 | Hindered disulfide drug conjugates | GENENTECH, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| WO-2019152440-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH INC (US) | 2017-04-27 | — | — | US | disclosed |
| WO-2017064675-A1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-9221841-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150191490-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20140018399-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8580828-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | SIRT3 1066/4885TDP1 179/4885KDM5A 608/4885 |
| US-20150191490-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | SIRT3 1094/4885TDP1 239/4885KDM5A 670/4885 |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | SIRT3 1299/4885TDP1 1333/4885KDM5A 1380/4885 |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | SIRT3 1299/4885TDP1 1333/4885KDM5A 1380/4885 |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | SIRT3 1299/4885TDP1 1333/4885KDM5A 1380/4885 |
| US-10729738-B2 | Hindered disulfide drug conjugates | STS, TST, SCLY | SIRT3 1406/4885TDP1 4712/4885KDM5A 2513/4885 |
| US-20140018399-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | SIRT3 1094/4885TDP1 239/4885KDM5A 670/4885 |
| US-11560381-B1 | Compounds and uses thereof | VHL, TFEB, BECN1 | SIRT3 1299/4885TDP1 1333/4885KDM5A 1380/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | SIRT3 1299/4885TDP1 1333/4885KDM5A 1380/4885 |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | STS, TST, SCLY | SIRT3 1406/4885TDP1 4712/4885KDM5A 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.